Two Sigma Investments
CYTO

Two Sigma Investments’s Altamira Therapeutics Ltd CYTO Stock Holding History

Two Sigma Investments’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40
Closed -$32K – 5060
2021
Q3 		$32K Buy
+40
New +$45.1K ﹤0.01% 4158

Other funds holding CYTO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments's CYTO Position: Q4 2021 in Review

Two Sigma Investments sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2021, closing a stake of 40 shares — an estimated $32K sold.

Two Sigma Investments first reported a position in CYTO in Q3 2021 and held it in 1 quarter. The position peaked at $32K in Q3 2021. 16 funds tracked by Wall St. Rank hold CYTO as of Q4 2021.

  • Two Sigma Investments reported no remaining Altamira Therapeutics Ltd position as of Q4 2021 after selling out during the quarter.
  • Two Sigma Investments sold 40 Altamira Therapeutics Ltd shares in Q4 2021, an estimated $32K.
  • Two Sigma Investments first reported a position in Altamira Therapeutics Ltd in Q3 2021 and held it in 1 quarter.
  • Two Sigma Investments's Altamira Therapeutics Ltd position peaked at $32K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2021.

Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.